ESMO 2018: Avelumab plus axitinib combination shows great promise as first-line treatment for advanced RCC
Results from the JAVELIN Renal 101 phase 3 study to [...]
Avelumab plus axitinib combination shows promise
A clinical trial looking at the combination of avelumab plus [...]
Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA
The European Association of Urology (EAU) Renal Cell Cancer Guidelines [...]
Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer
A recent article in Annals of Oncology reports new patient-reported outcomes [...]
Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
Alternative sunitinib dosing schedule
A recent study carried out by a Japanese research team [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
Latest clinical trial results for the treatment of kidney cancer
These short videos explain the latest results from the following [...]
Patient-reported outcomes for atezolizumab plus bevacizumab combination
Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]
Adjuvant therapy with TKIs has no benefit for high-risk kidney cancer
According to the results of a recent meta-analysis of three [...]
